48Q0 Stock Overview
A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
X4 Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.90 |
| 52 Week High | US$30.24 |
| 52 Week Low | US$4.90 |
| Beta | 0.73 |
| 1 Month Change | -6.41% |
| 3 Month Change | -63.31% |
| 1 Year Change | -80.01% |
| 3 Year Change | -85.01% |
| 5 Year Change | -97.84% |
| Change since IPO | -97.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 48Q0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | -0.9% |
| 1Y | -80.0% | -12.5% | 14.1% |
Return vs Industry: 48Q0 underperformed the German Biotechs industry which returned -13.4% over the past year.
Return vs Market: 48Q0 underperformed the German Market which returned 15.8% over the past year.
Price Volatility
| 48Q0 volatility | |
|---|---|
| 48Q0 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 48Q0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 48Q0's weekly volatility has decreased from 20% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 143 | Paula Ragan | www.x4pharma.com |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections.
X4 Pharmaceuticals, Inc. Fundamentals Summary
| 48Q0 fundamental statistics | |
|---|---|
| Market cap | €16.47m |
| Earnings (TTM) | €12.86m |
| Revenue (TTM) | €27.63m |
Is 48Q0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 48Q0 income statement (TTM) | |
|---|---|
| Revenue | US$31.36m |
| Cost of Revenue | US$5.51m |
| Gross Profit | US$25.85m |
| Other Expenses | US$11.25m |
| Earnings | US$14.60m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.52 |
| Gross Margin | 82.42% |
| Net Profit Margin | 46.54% |
| Debt/Equity Ratio | 329.6% |
How did 48Q0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 11:13 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |